Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges
Table 1
The characteristics of enrolled liver cancer patients grouped by the presence or absence of chronic liver disease.
Characteristics
Total (n = 93)
CLD (n = 72)
Non-CLD (n = 21)
value#
Age (years)
56.0 (29.0∼87.0)
53.5 (29.0∼87.0)
62.0 (42.0∼85.0)
0.026†
Sex (male/female)
68/25
55/17
13/8
0.188
Etiology (HBV/HCV/nonviral)
67/5/21
67/5/0
0/0/21
<0.001
Hemoglobin (g/L)
121.0 (59.0∼170.0)
121.0 (59.0∼170.0)
120.0 (62.0∼139.0)
0.358†
Albumin (g/L)
39.0 (24.0∼52.0)
38.0 (24.0∼52.0)
42.0 (25.0∼48.0)
0.410†
TB (μmol/L)
18.5 (5.0∼177.2)
19.2 (5.0∼177.2)
17.7 (5.2∼96.0)
0.748†
ALT (U/L)
27.0 (7.0∼332.0)
27.0 (7.0∼332.0)
31.0 (14.0∼69.0)
0.377†
AST (U/L)
38.0 (14.0∼244.0)
37.5 (14.0∼244.0)
38.0 (21.0∼82.0)
0.432†
ALBI score
−2.5 (−3.6∼−0.98)
−2.5 (−3.6∼−0.98)
−2.7 (−3.4∼−1.25)
0.607†
Child-Pugh score
6.0 (5.0–11.0)
5.5 (5.0∼11.0)
6.0 (5.0–11.0)
0.741†
Fibroscan value (kPa)
15.1 (6.0∼25.0)
15.7 (6.0∼25.0)
13.5 (6.0∼18.0)
0.116†
Spleen volume index (cm3)
1116.6 (351.7∼3566.6)
1244.1 (351.7∼3566.6)
751.7 (392.9∼1649.4)
0.007†
Combination with TPO or rhIL-11 (P/N)
30/63
24/48
6/15
0.681
Values are median (range); # value of the comparison between the CLD and non-CLD groups; †Mann–Whitney U test; Pearson χ.2 tests or Fisher’s exact test, as appropriate; abbreviations: CLD: chronic liver disease; HBV: hepatitis B virus; HCV; hepatitis C virus; TB: total bilirubin; ALT: alanine transaminase; AST: aspartate transaminase; ALBI score: albumin-bilirubin score; TPO: thrombopoietin; rhIL-11: recombinant human interleukin-11; P: positive; N: negative.
